yeah I would think there is significant weight placed on Phase 1 and phase 2 results as opposed to pre- clinical.
It is good what IMU are showing - but it’s still preclinical.
When IMU had Hervaxx preso last year it was PS this was phase 2.
Perhaps Asx has another beyond preclinical as PS
